Sensei Biotherapeutics (SNSE) Short Interest Ratio & Short Volume

Short interest is the volume of Sensei Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of February 28th, investors have sold 146,700 shares of SNSE short. 0.89% of Sensei Biotherapeutics' shares are currently sold short. Learn More on Sensei Biotherapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.89% of Sensei Biotherapeutics' floating shares are currently sold short.

Sensei Biotherapeutics saw a decline in short interest in February. As of February 28th, there was short interest totaling 146,700 shares, a decline of 14.1% from the previous total of 170,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Sensei Biotherapeutics currently has issued a total of 25,151,000 shares. Some of Sensei Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sensei Biotherapeutics currently has a public float of 16,480,000 shares.

0.89% of Sensei Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sensei Biotherapeutics: Eliem Therapeutics, Inc. (2.22%), Reviva Pharmaceuticals Holdings, Inc. (15.56%), OKYO Pharma Limited (1.38%), KALA BIO, Inc. (5.67%), Spero Therapeutics, Inc. (0.82%), FibroBiologics, Inc. (7.33%), Kezar Life Sciences, Inc. (0.76%), Dyadic International, Inc. (0.47%), Atara Biotherapeutics, Inc. (18.82%), Lantern Pharma Inc. (2.89%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks.

Short selling SNSE is an investing strategy that aims to generate trading profit from Sensei Biotherapeutics as its price is falling. SNSE shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Sensei Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SNSE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNSE, twice per month. The most recent reporting period available is February, 28 2025.